Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer-Reference-Cited by-同舟云学术

Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer

Published:2008-07-01 Issue:9 Volume:5 Page:512-520
ISSN:1743-4254
Container-title:Nature Clinical Practice Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Cameron David A,Stein Steven

Publisher

Springer Science and Business Media LLC

Subject

Oncology,General Medicine

Link

http://www.nature.com/articles/ncponc1156.pdf

Reference55 articles.

1. Dixon RB et al. (2004) Chapter 33: Cancer of the Breast: Section 1: Molecular Biology of Breast Cancer. In Cancer: Principles and Practice of Oncology, edn 7 (Eds DeVita VT. et al.) Philadelphia: Lippincott Williams & Wilkins

2. Linggi B and Carpenter G (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16: 649–656

3. Xia W et al. (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23: 646–653

4. Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

5. Cobleigh MA et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs;Bioorganic Chemistry;2024-12

2. Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors;Anti-Cancer Agents in Medicinal Chemistry;2023-05

3. Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update;Frontiers in Pharmacology;2023-01-09

4. Reverse Engineering Drugs: Lorcaserin as an Example;Advances in Neurobiology;2023

5. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors;Bioorganic Chemistry;2022-11